ERBB2 and breast carcinoma: Although the trial was terminated prematurely, due to recruitment difficulty, the study suggested that patients with HER2-positivity can respond to T-DM1, thereby potentially informing the use of T-DM1 in HER2-positive non-breast cancers [58].